Sehn LH, Kamdar M, Herrera AF, et al. Adding polatuzumab vedotin (pola) to bendamustine and rituximab (BR) treatment improves survival in patients with relapsed/refractory DLBCL: results of a phase 2 clinical trial. EHA 2018, abstract S802.
ADVANCE-II-studie officieel van start
nov 2018 | Leukemie, Vaccinatie